Quoin Pharmaceuticals, Ltd. (QNRX)
$4.10-1.20%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8M
- Beta
- 1.66
- P/E (TTM)
- -0.27
- Short % float
- 4.54%
- Days to cover
- 1.4
- SI change
- -48.2%
- 1W
- -12.77%
- 1M
- -39.71%
- vs SPY 1W
- -11.79%
- vs SPY 1M
- -41.57%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 8
- VALUE
- 5
- GROWTH
- 37
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-182.9%
REV YoY-
ROE-304.9%
EPS YoY-
ROA-156.7%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.27
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B2.09
P/FCF-
EV/EBITDA-0.23
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO1.76
ND/EBITDA-
BETA1.66
Company news
FAQ
- What is LOPJLB’s current signal on QNRX?
- LOPJLB’s latest quantitative signal on Quoin Pharmaceuticals, Ltd. (QNRX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is QNRX in?
- Quoin Pharmaceuticals, Ltd. (QNRX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Quoin Pharmaceuticals, Ltd. (QNRX) do?
- Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX00…